Search Within

Colleen Dorsey

Formats
  1. Meeting Abstract (11)
  2. Journal Article (5)
Groups
  1. Department of Medicine (15)
  2. Hematologic Malignancies, Division of (15)
  3. Adult Leukemia (14)
  4. Center for Hematologic Malignancies (14)
  5. Lymphoma (8)
  6. Nursing (7)

More Groups

People
  1. Anthony Mato (14)
  2. Lindsey Roeker (13)
  3. Andrew Zelenetz (8)
  4. Julie Goodfriend (5)
  5. Katherine Whitaker (3)
  6. Lisa Sarmasti (3)

More People

Years
  1. 2022 (2)
  2. 2021 (1)
  3. 2020 (4)
  4. 2019 (7)
  5. 2018 (2)
Publications
  1. Blood (4)
  2. Clinical Cancer Research (3)
  3. Hematological Oncology (3)
  4. Leukemia and Lymphoma (3)
  5. Blood Advances (1)
  6. Journal of Clinical Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (5)
  2. American Association for Cancer Research (3)
  3. Taylor & Francis Group (3)
  4. Wiley Blackwell (3)
  5. American Society of Clinical Oncology (1)
  6. Oncology Nursing Society (ONS) (1)

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Hypertension (HTN) in patients (pts) treated with ibrutinib (IBR) for chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Sarraf Yazdy, M.; Roeker, L.; Gashonia, L.; Goodfriend, J.; Narkhede, M.; Rhodes, J.; Kennard, K.; Morse, H.; Dorsey, C.; Battiato, K.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • A phase 2 study to assess the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy
    Meeting Abstract

    Mato, A. R.; Schuster, S. J.; Lamanna, N.; Pagel, J. M.; Flinn, I. W.; Barrientos, J.; Reeves, J. A.; Cheson, B. D.; Barr, P. M.; Kambhampati, S.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Phase I/II study of umbralisib (TGR‐1202) in combination with ublituximab (TG‐1101) and pembrolizumab in patients with REL/REF CLL and Richter's transformation
    Meeting Abstract

    Mato, A. R.; Svoboda, J.; Luning Prak, E. T.; Schuster, S. J.; Tsao, P. Y.; Dorsey, C.; Sarmasti, L. M.; Becker, P. S.; Brander, D. M.; Nasta, S.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL
    Journal Article

    Mato, A. R.; Roeker, L. E.; Eyre, T. A.; Nabhan, C.; Lamanna, N.; Hill, B. T.; Brander, D. M.; Barr, P. M.; Lansigan, F.; Cheson, B. D.; more...
    Blood Advances (2019)

    Fulltext@MSK | Save
  • Phase I/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed/refractory CLL and Richter's transformation
    Meeting Abstract

    Mato, A. R.; Svoboda, J.; Prak, E. T. L.; Schuster, S. J.; Tsao, P.; Dorsey, C.; Becker, P. S.; Brander, D. M.; Nasta, S. D.; Landsburg, D. J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy
    Meeting Abstract

    Mato, A. R.; Schuster, S. J.; Lamanna, N.; Flinn, I.; Barrientos, J. C.; Kambhampati, S.; Cheson, B. D.; Barr, P. M.; Pagel, J. M.; Reeves, J. A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save